문영철(文映喆) 교수
의과대학
- 02-2650-2777
- 면담 가능시간
- 목, 금 오후 4시-6시
연구실적
- Clinical significance of bone marrow involvement by immunoglobulin gene rearrangement in de novo diffuse large B-cell lymphoma: a multicenter retrospective study Frontiers in Oncology, 2024, v.14, 1363385
- Initial Low-Dose Hydroxyurea and Anagrelide Combination in Essential Thrombocythemia: Comparable Response with Lower Toxicity Journal of Clinical Medicine, 2024, v.13 no.10, 2901
- Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913) Cancer Research and Treatment, 2024, v.56 no.3, 956-966
- A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients with Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone American Journal of Gastroenterology, 2023, v.118 no.8, 1373-1380
- Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study FRONTIERS IN ONCOLOGY, 2023, v.13, 998014
- Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study CANCER RESEARCH AND TREATMENT, 2023, v.55 no.4, 1355-1362
- Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, v.38 no.41, e328
- Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170) FRONTIERS IN ONCOLOGY, 2023, v.13, 1209110
- Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high-risk essential thrombocythemia Cancer Medicine, 2023, v.12 no.7, 8073-8082
- Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation Blood Cancer Journal, 2023, v.13 no.1, 95
- Ultrasound-guided percutaneous core needle biopsy of abdominal subcutaneous fat for diagnosing amyloidosis: comparison with bone marrow biopsy Acta Radiologica, 2023, v.64 no.5, 1770-1774
- A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naive, high-risk essential thrombocythemia as a primary treatment FRONTIERS IN ONCOLOGY, 2022, v.12, 989984
- Long-term follow-up results of cytarabine-contain-ing chemotherapy for acute promyelocytic leukemia Korean Journal of Internal Medicine, 2022, v.37 no.4, 841-850
- Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia The Korean Journal of Internal Medicine, 2022, v.37 no.4, 841-850
- Management of immune thrombocytopenia: 2022 update of Korean experts recommendations Blood Research, 2022, v.57 no.1, 20-28
- Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909) Bone Marrow Transplantation, 2022, v.57 no.12, 1797-1802
- Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma Cancer Research and Treatment, 2022, v.54 no.2, 597-612
- Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology Clinical Lymphoma, Myeloma and Leukemia, 2022, v.22 no.10, e931-e937
- Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma Annals of Hematology, 2022, v.101 no.6, 1217-1226
- Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw: a prospective clinical study Osteoporosis International, 2022, v.33 no.2, 367-377
- Suppressive effect of α-mangostin for cancer stem cells in colorectal cancer via the Notch pathway BMC Cancer, 2022, v.22 no.1, 341
- Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone International Journal of Hematology, 2021, v.113 no.1, 81-91
- Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia HEMATOLOGY, 2021, v.26 no.1, 904-913
- Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia The Lancet Regional Health - Western Pacific, 2021, v.10, 100126
- Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia International Journal of Hematology, 2021, v.114 no.3, 355-362
- Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-18-FDG PET/CT BLOOD CANCER JOURNAL, 2021, v.11 no.12, 190
- Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma Supportive Care in Cancer, 2021, v.29 no.9, 4969-4977
- Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis KOREAN JOURNAL OF INTERNAL MEDICINE, 2021, v.36 no.5, 1181-1189
- The 2020 revision of the guidelines for the management of myeloproliferative neoplasms KOREAN JOURNAL OF INTERNAL MEDICINE, 2021 , 45-62
- A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis ANNALS OF HEMATOLOGY, 2020, v.99 no.6, 1283-1291
- Emergence of Monosomy 7 in Philadelphia-Negative Cells during MDS Development and not CML Diagnosis Proved by Serial Droplet Digital PCR Laboratory Medicine Online, 2020, v.10 no.4, 321-325
- Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis LEUKEMIA & LYMPHOMA, 2020, v.61 no.11, 2714-2721
- Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) BRITISH JOURNAL OF HAEMATOLOGY, 2020, v.189 no.2, 303-312
- Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia JOURNAL OF CLINICAL MEDICINE, 2020, v.9 no.7, 2310
- Peroxiredoxin 3 has important roles on arsenic trioxide induced apoptosis in human acute promyelocytic leukemia cell line via hyperoxidation of mitochondrial specific reactive oxygen species Molecules and Cells, 2020, v.43 no.9, 813-820
- Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study) American Journal of Hematology, 2020, v.95 no.4, 0
- Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia YONSEI MEDICAL JOURNAL, 2020, v.61 no.6, 452-459
- The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study) Annals of Hematology, 2020, v.99 no.2, 309-319
- A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study Biology of Blood and Marrow Transplantation, 2019, v.25 no.7, 1312-1319
- Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, v.19 no.10, 656-664
- Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis ANNALS OF HEMATOLOGY, 2019, v.98 no.10, 2273-2281
- Degranulated Eosinophils Contain More Fine Nerve Fibers in the Duodenal Mucosa of Patients With Functional Dyspepsia JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2019, v.25 no.2, 212-221
- Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy Thrombosis Research, 2019, v.183, 131-135
- Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, v.34 no.5, 1125-1135
- Somatic mutation of HLA-DRB1*04:03 in a patient with myelodysplastic syndrome at diagnosis HLA, 2019, v.93 no.4, 216-219
- Clinicopathological characteristics of hyperdiploidy with high-risk cytogenetics in multiple myeloma Annals of Laboratory Medicine, 2018, v.38 no.2, 160-164
- Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP) JOURNAL OF KOREAN MEDICAL SCIENCE, 2018, v.33 no.19
- GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms ANNALS OF LABORATORY MEDICINE, 2018, v.38 no.4, 296-
- Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients ANNALS OF HEMATOLOGY, 2018, v.97 no.6, 955-965
- Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01 CANCER RESEARCH AND TREATMENT, 2018, v.50 no.2, 590-598
- Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150) BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, v.24 no.5, 923-929
- Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/IINK/T-cell lymphoma ANNALS OF ONCOLOGY, 2018, v.29 no.1, 256-263
- The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma ACTA HAEMATOLOGICA, 2018, v.140 no.3, 146-156
- 진단초기 만성호산구백혈병으로 오진한 호산구증가증과 복합핵형을 나타낸 역형성큰세포림프종 LABORATORY MEDICINE ONLINE, 2018, v.8 no.2, 56~61
- 혈액종양 진단 시에 관찰되는 자연살해세포활성의 다양성 LABORATORY MEDICINE ONLINE, 2018, v.8 no.2, 41~51
- A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma ONCOTARGET, 2017, v.8 no.23, 37605-37618
- Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy American Journal of Hematology, 2017, v.92 no.12, 1280-1286
- Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma ONCOTARGET, 2017, v.8 no.54, 92171-92182
- Lymphedema associated with primary amyloidosis: A case study Annals of Rehabilitation Medicine, 2017, v.41 no.5, 887-891
- Management of immune thrombocytopenia: Korean experts recommendation in 2017 Blood Research, 2017, v.52 no.4, 254-263
- Neutrophilic Leukemoid Reaction Associated with Malignancy Initially Suspected as Chronic Neutrophilic Leukemia Laboratory Medicine Online, 2017, v.7 no.4, 206~210
- Novel deletion mutation of HLA-B*40:02 gene in acquired aplastic anemia HLA, 2017, v.89 no.1, 47-51
- Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia CLINICAL CANCER RESEARCH, 2017, v.23 no.23, 7180-7188
- The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160) ONCOTARGET, 2017, v.8 no.45, 79517-79526
- VARIABLE NATURAL KILLER CELL ACTIVITY IN HEMATOLOGIC MALIGNANCIES AT DIAGNOSIS INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, v.39, 92-92
- ACQUIRED HLA-B*40:02 MUTATION LEADING TO FRAME SHIFT IN DIOPATHIC APLASTIC ANEMIA HAEMATOLOGICA, 2016, v.101, 714-714
- CLINICOPATHOLOGIC CHARACTERISTICS ASSOCIATED WITH NATURAL KILLER CELL ACTIVITY BY MEASUREMENT OF INTERFERON-GAMMA IN HEMATOLOGIC MALIGNANCIES HAEMATOLOGICA, 2016, v.101, 661-661
- Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients Leukemia and Lymphoma, 2016, v.57 no.2, 341-347
- Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study ONCOTARGET, 2016, v.7 no.44, 72033-72043
- Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study HAEMATOLOGICA, 2016, v.101 no.6, 717-723
- MITOCHONDRIAL SPECIFIC ROS HYPEROXIDATION VIA PEROXIREDOXIN III HAS IMPORTANT ROLES ON ARSENIC TRIOXIDE INDUCED APOPTOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA HAEMATOLOGICA, 2016, v.101, 672-672
- Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome PLOS ONE, 2016, v.11 no.11
- The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea ANNALS OF HEMATOLOGY, 2016, v.95 no.6, 911-919
- Two Cases of Medical Device-Related Corynebacterium striatum Infection: A Meningitis and A Sepsis Annals of Clinical Microbiology, 2016, v.19 no.1, 28-31
- A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome Oncotarget, 2015, v.6 no.42, 44985-44994
- Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome ACTA HAEMATOLOGICA, 2015, v.134 no.1, 40-48
- CLINICOPATHOLOGIC CHARACTERISTICS OF UNCLASSIFIABLE MYELOPROLIFERATIVE NEOPLASMS HAEMATOLOGICA, 2015, v.100, 756-756
- Calreticulin mRNA expression and clinicopathological characteristics in acute myeloid leukemia CANCER GENETICS, 2015, v.208 no.12, 630-635
- Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma Biology of Blood and Marrow Transplantation, 2015, v.21 no.9, 1597-1604
- Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial BLOOD, 2015, v.126 no.23
- Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study Annals of Hematology, 2015, 24 NOV 2015, 1-8
- Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, v.37 no.2, 181-189
- INTERNATIONAL EXTRANODAL NK/T-CELL LYMPHOMA PROJECT: PROGNOSTIC FACTORS IN THE ERA OF NONANTHRACYCLINE-BASED TREATMENT HAEMATOLOGICA, 2015, v.100, 5-5
- MUTATION ANALYSIS OF JAK2, MPL, CALR, ASXL1, TET2, IDH1, IDH2, DNMT3A, AND SF3B1 IN MYELOPROLIFERATIVE NEOPLASM HAEMATOLOGICA, 2015, v.100, 530-530
- Manipulation of beta-catenin pathway to overcome endocrine resistance in breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 2015, v.33 no.15
- Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia Blood, 2015, v.126 no.6, 746-756
- PREDICTIVE FACTORS FOR TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH IMATINIB-TREATED, UNDETECTABLE MOLECULAR RESIDUAL DISEASE: RESULTS FROM THE KID STUDY HAEMATOLOGICA, 2015, v.100, 433-434
- Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib BLOOD, 2015, v.126 no.23
- Submicroscopic Deletions of Immunoglobulin Heavy Chain Gene (IGH) in Precursor B Lymphoblastic Leukemia with IGH Rearrangements ANNALS OF LABORATORY MEDICINE, 2015, v.35 no.1, 128-131
- The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea Korean Journal of Internal Medicine, 2015, v.30 no.5, 675-683
- Treatment outcomes of rituximab plus hyper-CVAD in korean patients with sporadic burkitt or burkitt-like lymphoma: Results of a multicenter analysis Cancer Research and Treatment, 2015, v.47 no.2, 173-181
- Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy Journal of Clinical Virology, 2015, v.73, 64-69
- Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL) EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, v.94 no.6, 504-510
- Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: A prospective multicenter study BioMed Research International, 2014
- Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study Annals of Hematology, 2014, v.93 no.8, 1353-1361
- Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenstrom Macroglobulinemia in Korea BIOMED RESEARCH INTERNATIONAL, 2014
- ETV6/RUNX1 Rearrangement Identified by RT-PCR without Evidence on FISH ACTA HAEMATOLOGICA, 2014, v.132 no.1, 122-124
- Effect of anemia correction on left ventricular structure and filling pressure in anemic patients without overt heart disease KOREAN JOURNAL OF INTERNAL MEDICINE, 2014, v.29, 445-453
- Incidence of venous thromboembolism following major surgery in Korea: From the Health Insurance Review and Assessment Service database Journal of Thrombosis and Haemostasis, 2014, v.12 no.7
- Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients ANNALS OF HEMATOLOGY, 2014, v.93 no.1, 113-121
- Prevention of Venous Thromboembolism, 2nd Edition : Korean Society of Thrombosis and Hemostasis Evidence-Based Clinical Practice Guidelines JOURNAL OF KOREAN MEDICAL SCIENCE, 2014, v.29 no.2, 164-171
- Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies : A Multicenter, Prospective, Open-Label, Observational Study in Korea JOURNAL OF KOREAN MEDICAL SCIENCE, 2014, v.29 no.1, 61-68
- The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis : a multicenter, prospective, open-label, observational study in Korea ANNALS OF HEMATOLOGY, 2014, v.93 no.1, 33-42
- Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer TUMORI, 2014, v.100 no.1, 80-86
- Topoisomerase II alpha and microtubuleassociated protein-tau as a predictive marker in axillary lymph node positive breast cancer Tumori, 2014, v.100 no.1, 80-86
- Transplant physicians' perceptions of cord blood transplantation in Korea: A questionnaire survey Blood Research, 2014, v.49 no.4, 228-233
강의
-
2025-1학기
-
내과학실습Ⅳ
- 학수번호 37644분반 01
- 3학년 ( 4학점 , 220시간)
- 전공필수 의학과 외 수강불가, 팀티칭, 자체시간표에 따라 운영
-
-
2024-2학기
-
혈액및종양
- 학수번호 37624분반 01
- 2학년 ( 3학점 , 65시간)
- 전공필수 전공필수 팀티칭, 의학과 외 수강불가, 마곡 104호, 자체시간표에 따른 운영
-
-
2024-1학기
-
내과학실습Ⅳ
- 학수번호 37644분반 01
- 3학년 ( 4학점 , 220시간)
- 전공필수 의학과 외 수강불가, 팀티칭, 자체시간표에 따라 운영
-
-
2023-2학기
-
혈액및종양
- 학수번호 37624분반 01
- 2학년 ( 3학점 , 65시간)
- 전공필수 전공필수 팀티칭, 의학과 외 수강불가, 마곡 104호, 자체시간표에 따른 운영
-
내과학실습Ⅳ
- 학수번호 37644분반 01
- 3학년 ( 4학점 , 220시간)
- 전공필수 전공필수 팀티칭, 의학과 외 수강불가, 자체시간표에 따른 운영
-
-
2023-1학기
-
내과학실습Ⅳ
- 학수번호 37644분반 01
- 3학년 ( 4학점 , 220시간)
- 전공필수 의학과 외 수강불가, 팀티칭, 자체시간표에 따라 운영
-
-
2022-2학기
-
혈액및종양
- 학수번호 37624분반 01
- 2학년 ( 3학점 , 65시간)
- 전공필수 전공필수 팀티칭, 의학과 외 수강불가, 마곡 104호, 자체시간표에 따른 운영
-
내과학실습Ⅳ
- 학수번호 37644분반 01
- 3학년 ( 4학점 , 220시간)
- 전공필수 전공필수 팀티칭, 의학과 외 수강불가, 자체시간표에 따른 운영
-
-
2022-1학기
-
내과학실습Ⅳ
- 학수번호 37644분반 01
- 3학년 ( 4학점 , 220시간)
- 전공필수 의학과 외 수강불가, 팀티칭, 자체시간표에 따라 운영
-
서브인턴
- 학수번호 37681분반 01
- 4학년 ( 2학점 , 50시간)
- 전공필수 의학과 외 수강불가, 팀티칭, 자체시간표에 따라 운영
-
학력
영남대학교 의학박사(의학과)